Searle’s Calan SR
Executive Summary
Launch of new 180 mg dose of the sustained-release verapamil product includes a three-month giveaway program to consumers. Searle used a similar approach in launching its beta blocket Kerlone earlier this year. Calan SR, a once-a-day treatment for hypertension, has been available since 1986 at a 240 mg dose. The new dosage is entering the market at the same time as a potential major competitor from Lederle with help from Wyeth-Ayerst.